Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Westin SN, et al. Among authors: nick am. Am J Obstet Gynecol. 2021 Feb;224(2):191.e1-191.e15. doi: 10.1016/j.ajog.2020.08.032. Epub 2020 Aug 15. Am J Obstet Gynecol. 2021. PMID: 32805208 Free PMC article. Clinical Trial.
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.
Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Hwang JY, et al. Among authors: nick am. Cancer Res. 2008 Jul 15;68(14):5849-58. doi: 10.1158/0008-5472.CAN-07-6130. Cancer Res. 2008. PMID: 18632639 Free PMC article.
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Lin YG, et al. Among authors: nick am. Clin Cancer Res. 2008 Sep 1;14(17):5437-46. doi: 10.1158/1078-0432.CCR-07-4922. Clin Cancer Res. 2008. PMID: 18765535 Free PMC article.
Functional significance of VEGFR-2 on ovarian cancer cells.
Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Spannuth WA, et al. Among authors: nick am. Int J Cancer. 2009 Mar 1;124(5):1045-53. doi: 10.1002/ijc.24028. Int J Cancer. 2009. PMID: 19058181 Free PMC article.
Dicer, Drosha, and outcomes in patients with ovarian cancer.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Merritt WM, et al. Among authors: nick am. N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785. N Engl J Med. 2008. PMID: 19092150 Free PMC article.
Dual targeting of EphA2 and FAK in ovarian carcinoma.
Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Shahzad MM, et al. Among authors: nick am. Cancer Biol Ther. 2009 Jun;8(11):1027-34. doi: 10.4161/cbt.8.11.8523. Epub 2009 Jun 24. Cancer Biol Ther. 2009. PMID: 19395869 Free PMC article.
Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Mangala LS, et al. Among authors: nick am. Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26. Clin Cancer Res. 2009. PMID: 19470734 Free PMC article.
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. Lee JW, et al. Among authors: nick am. J Natl Cancer Inst. 2009 Sep 2;101(17):1193-205. doi: 10.1093/jnci/djp231. Epub 2009 Jul 29. J Natl Cancer Inst. 2009. PMID: 19641174 Free PMC article.
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Merritt WM, et al. Among authors: nick am. Cancer Biol Ther. 2009 Aug;8(16):1596-603. doi: 10.4161/cbt.8.16.9004. Epub 2009 Aug 13. Cancer Biol Ther. 2009. PMID: 19738426 Free PMC article.
121 results